Pharma News

Amgen to buy Horizon Therapeutics in $26.4B deal

Amgen, biotech drug developer, said it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market.

The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.

Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.

Read more at Associated Press

Source link
#Amgen #buy #Horizon #Therapeutics #26.4B #deal

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *